{"id":53632,"date":"2023-02-03T23:02:21","date_gmt":"2023-02-03T22:02:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/"},"modified":"2023-02-03T23:02:21","modified_gmt":"2023-02-03T22:02:21","slug":"intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/","title":{"rendered":"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders"},"content":{"rendered":"
\n

BETHESDA, Md.–(BUSINESS WIRE)–$IQMD<\/a>–Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) (the \u201cCompany\u201d) announced today that it has postponed the Company\u2019s Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern Time. The postponed Special Meeting will be completely virtual, and stockholders will be able to attend the special meeting online, vote and submit questions by visiting https:\/\/www.cstproxy.com\/iqmdspac\/2023<\/a>. There will be no change in the record date as a result of this postponement or the date by which stockholders must have elected to redeem their public shares, and proxies tendered prior to the postponed date will not need to be voted again.\n<\/p>\n

\nStockholders may elect to redeem their public shares for a pro-rata portion of the funds held in the Trust Account, by no later than February 6, 2023, by tendering their shares either by delivering their share certificates to the transfer agent or by delivering their shares electronically using the Depository Trust Company\u2019s DWAC (Deposit\/Withdrawal At Custodian) system. If you hold your shares in street name, you will need to instruct your bank, broker or other nominee to withdraw the shares from your account in order to exercise your redemption rights.\n<\/p>\n

\nThe Company\u2019s stockholders and other interested persons are advised to read the proxy statement. Stockholders are also able to obtain copies of the proxy statement and other relevant materials filed with the Securities and Exchange Commission (the \u201cSEC\u201d), without charge, at the SEC\u2019s web site at www.sec.gov<\/a>, or by directing a request to the Company\u2019s proxy solicitor Morrow Sodali LLC, at (800) 662-5200 (toll free), or brokers and banks may call collect (203) 658-9400 You may contact Morrow Sodali by email at OLIT@investor.morrowsodali.com<\/a>.\n<\/p>\n

\nForward Looking Statements<\/b>\n<\/p>\n

\nThis press release contains statements that constitute \u201cforward-looking statements.\u201d No assurance can be given that the Company will ultimately complete a business combination transaction. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company\u2019s Annual Report on Form 10-K and subsequent reports filed with the SEC. Copies of these documents are available on the SEC\u2019s website, at www.sec.gov<\/a>. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBrian Ruby, ICR, brian.ruby@icrinc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BETHESDA, Md.–(BUSINESS WIRE)–$IQMD–Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) (the \u201cCompany\u201d) announced today that it has postponed the Company\u2019s Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern Time. The postponed Special Meeting will be completely virtual, and stockholders will be … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53632","6":"format-standard","7":"category-industry"},"yoast_head":"\nIntelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BETHESDA, Md.–(BUSINESS WIRE)–$IQMD–Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) (the \u201cCompany\u201d) announced today that it has postponed the Company\u2019s Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern Time. The postponed Special Meeting will be completely virtual, and stockholders will be ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T22:02:21+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders\",\"datePublished\":\"2023-02-03T22:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/\"},\"wordCount\":424,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/\",\"name\":\"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-02-03T22:02:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/","og_locale":"en_US","og_type":"article","og_title":"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders - Pharma Trend","og_description":"BETHESDA, Md.–(BUSINESS WIRE)–$IQMD–Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) (the \u201cCompany\u201d) announced today that it has postponed the Company\u2019s Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern Time. The postponed Special Meeting will be completely virtual, and stockholders will be ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-03T22:02:21+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders","datePublished":"2023-02-03T22:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/"},"wordCount":424,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/","url":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/","name":"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-02-03T22:02:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/intelligent-medicine-acquisition-corp-announces-adjournment-of-special-meeting-of-stockholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53632"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53632\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}